文献速递支持与姑息治疗

2024年全球感染归因癌症负担:全球发病率分析

Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.
PubMed 文献 · Lancet Oncol · 2026-01-01

该全球发病率分析利用GLOBOCAN 2024年癌症发病数据,估算12种IARC 1类致癌物归因的新发癌症病例数、人群归因分数(PAF)和年龄标准化发病率(ASIR)。

要点

  • 幽门螺杆菌(76万例,PAF 4%)和HPV(75万例,PAF 4%)是主要归因病原体。

研究设计与样本

  • 全球发病率分析,基于GLOBOCAN 2024年癌症发病数据,估算12种IARC 1类致癌物归因的PAF、绝对病例数和ASIR。
  • 按性别、国家和年龄组分层的估计值汇总至联合国地理次区域和世界银行收入组。

主要发现

  • 归因病例数最多的病原体为幽门螺杆菌(76万例,PAF 4%),其次为HPV(75万例,4%)、HBV(36万例,2%)、EBV(26万例,1%)和HCV(16万例,<1%)。
  • EBV归因癌症的癌种分布存在区域差异。

临床怎么用

  • 应加强HPV和HBV疫苗接种、HIV/幽门螺杆菌/HBV/HCV检测与治疗、安全注射实践、安全套和暴露前预防可及性,以及HPV相关宫颈癌和肛门癌的癌前病变筛查。
  • 研究结果可为新预防工具(尤其是EBV)的研发投资提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infectious agents are an important preventable cause of cancer globally. To inform prevention efforts, we provide a comprehensive picture of cancer burden attributable to infections, including newly established, carcinogenic infectious agents and latest global cancer incidence estimates. METHODS: In this worldwide incidence analysis, we used data from the Global Cancer Observatory's Cancer Today (GLOBOCAN) database of cancer incidence in 2024 to estimate population-attributable fractions (PAFs), absolute numbers, and age-standardised incidence rates (ASIRs) of new cancer cases attributable to 12 infectious agents classified as Group 1 carcinogens by the IARC Monographs Programme: Helicobacter pylori, human papillomavirus (HPV), hepatitis B (HBV) and hepatitis C viruses (HCV), Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus, Schistosoma haematobium, human T-cell lymphotropic virus, Opisthorchis viverrini, Clonorchis sinensis, Merkel cell polyomavirus, and HIV. Estimates stratified by sex, country, and age group were aggregated by UN geographical subregion and World Bank income group. FINDINGS: An estimated 2·3 million new cancer cases were attributable to infections globally in 2024, which is equivalent to 12% of all cancer cases. The largest number of cases was attributable to H pylori (n=760 000, PAF 4%), followed by HPV (n=750 000, 4%), HBV (n=360 000, 2%), EBV (n=260 000, 1%), and HCV (n=160 000, <1%). The largest burden of infection-attributable cancer was in eastern Asia, with 990 000 cases (42% of the global total, ASIR 31·9 per 100 000 cases). ASIRs were also higher than the global average (22·7) in sub-Saharan Africa (28·5), central and eastern Europe (24·3), and southeastern Asia (23·1). Focused analysis of EBV-attributable cancers revealed regional variation in the distribution of cancer types. INTERPRETATION: Our findings highlight the importance of infection control to achieve cancer prevention. Scientifically proven, but often underused, approaches include HPV and HBV vaccination; testing and treatment of HIV, H pylori, HBV, and HCV; safe injection practices; access to condoms and pre-exposure prophylaxis to prevent HIV transmission; and screening of precancerous lesions for HPV-driven cervical and anal cancer. Our findings also inform the investment cases for research and development for new prevention tools, most notably for EBV. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rumgay H, Georges D, Huang Y, et al. Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis. Lancet Oncol. 2026. PMID: 42805198. doi:10.1016/S1470-2045(26)00307-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。